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Multiple chemical sensitivity is a controversial diagnosis. Rigorous, controlled, laboratory-based
research can reduce this controversy and lead to potential clinical confirmatory tests. The
literature on human caffeine discrimination provides a rigorous methodology that can address
reports that patients who suffer multiple chemical sensitivity (MCS) are sensitive to usually well-
tolerated chemical doses; the studies require patients to discriminate caffeine from placebo
under double-blind conditions. Several issues relevant to the conduct of caffeine discrimination
studies using MCS patients as subjects are addressed; these issues include study design,
determination of safe and tolerable training doses, and discrimination training. Such research will
benefit patients and clinicians dealing with a diagnosis of MCS. Environ Health Perspect
105(Suppl 2):509-513 (1997)
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Introduction
A diagnosis ofmultiple chemical sensitivity
(MCS) is controversial, in part because the
term means different things to different
people. For the MCS patient seeking treat-
ment, the term can mean an adverse and
often medically unrecognized condition
marked by a variety of symptoms (e.g.,
lethargy, fatigue, memory difficulties,
shortness of breath) that can arise from
exposure to previously tolerated chemical
stimuli (e.g., car exhaust, perfume, alcohol
or caffeine) (1). For the clinician attempt-
ing to treat the MCS patient, the term can
mean a disorder with no accepted diagnos-
tic criteria or confirmatory laboratory
markers and few treatments. To the
researcher interested in studying MCS, the
term represents the difficult empirical
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problem ofstudying a condition that may
require exposure to potentially aversive or
toxic stimuli. The purpose ofthis report is
to suggest a powerful empirical method
that can be used to study MCS in humans:
drug discrimination using caffeine as a dis-
criminative stimulus. Before describing this
methodology and its potential applications,
we first provide a briefoverview of MCS.
We then discuss the variability in the range
ofcaffeine doses that can be detected across
subjects and the types ofsubjective effects
that are reported by normal human volun-
teers who participate in caffeine discrimi-
nation studies. We also discuss how MCS
patients may represent a special population
that is exquisitely sensitive to caffeine's
effects. Finally, we suggest issues that
researchers should consider when planning
research in caffeine discrimination involv-
ing volunteer MCS patients. Such research
should positively impact MCS patients and
clinicians as they deal with a debilitating
but ill-defined disorder.
What is Multiple Chemical
Sensitivity?
While many definitions exist (2,3), the
term MCS is most often applied to an
acquired non-IgE-mediated reaction in one
or more organ systems to normally non-
toxic chemical stimuli. MCS patients often
report a wide range ofsymptoms that are
elicited by various stimuli. For example, in
a recent study of 112 MCS patients, the
four most frequently reported symptoms
were "tired or lethargic," "fatigue > 6
months," "memory difficulties," and "diffi-
culty concentrating" (1,2). While many
respondents reported that their symptoms
could be elicited by airborne stimuli (diesel
or gas engine exhaust, perfume, etc.), a
substantial proportion of respondents also
implicated ingested items as symptom elici-
tors, including alcohol, chlorinated water,
and cane sugar. Some 30% or more of
respondents indicated that caffeine-con-
taining items (chocolate, cola, coffee, or
tea) elicited their symptoms (1). Such evi-
dence might imply that MCS patients,
especially those who report sensitivity to
dietary sources ofcaffeine, may represent a
special population exquisitely sensitive to
low-dose caffeine.
In part because MCS patients report
that so many inhaled and ingested chemi-
cal stimuli elicit symptoms, and also
because elicited symptoms vary markedly
across individuals, a diagnosis of MCS is
controversial (1,4,5). Several professional
organizations have found no current evi-
dence to support the diagnosis of MCS or
to support clinical ecology, the branch of
medicine created to treat the disorder (6-9).
However, many of these same organiza-
tions recognize the need for well-controlled
laboratory studies of the phenomenon
(7,8). The fact that many MCS patients
report sensitivity to caffeine, coupled with
a thriving caffeine discrimination litera-
ture, suggests that caffeine discrimination
methodology may be an excellent starting
point for well-controlled studies ofMCS.
Caffeine Discrimination in
Normal Human Volunteers
Several well-controlled studies have investi-
gated caffeine discrimination using normal
human volunteers. Typically, these studies
involve intensive, within-subject presenta-
tions ofplacebo and active doses ofcaffeine
over the course ofmany discrete trials. For
example, Mumford et al. (10) reported the
results of a caffeine discrimination study
involving seven subjects who participated
in 30 to 100 trials (1 trial per day). On
each trial, subjects were asked to discrimi-
nate placebo from an active caffeine dose.
As described below, this study, or others
using a similar methodology, demonstrate
that there is considerable individual vari-
ability in the range ofdoses ofcaffeine that
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can be discriminated from placebo, and
that caffeine challenge can produce either
positively or negatively rated subjective
effects depending upon caffeine dose. Also,
people who do not use caffeine report that
caffeine produces more aversive effects
than people who do use caffeine regularly
(11). These results are consistent with the
hypothesis that some individuals (e.g.,
MCS patients) may be extremely sensitive
to caffeine and that, for these individuals,
dietary doses ofcaffeine may be aversive.
First, the range ofcaffeine doses that are
reliably detected by normal volunteers
varies widely across individuals (12,13). For
example, Griffiths et al. (12) reported a
study ofseven caffeine users who abstained
from all dietary caffeine, and then were
trained to discriminate 100 (n = 1) or 178
(n = 6) mg caffeine from placebo. After
learning the discrimination, all subjects
were tested to determine the lowest caffeine
dose that they could reliably discriminate
from placebo. Results indicated individual
differences in the threshold ofcaffeine dis-
crimination, ranging from a low of 10 mg
to a high of 56 mg caffeine (Figure 1).
Other reports involving explicit discrimina-
tion training oflow-dose caffeine indicate
that about 70% ofsubjects can detect 56
mg or less ofcaffeine, and 35% ofsubjects
can detect 18 mg or less ofcaffeine (14).
These results clearly indicate that, in the
normal human population, there is consid-
erable variability in sensitivity to caffeine.
The determinants ofthis variability have not
been systematically studied. Factors that
would probably contribute to such variabil-
ity might include the extent ofprior caffeine
exposure and the choice of measurement
technique. Nonetheless, a methodology
clearly exists for measuring sensitivity to
low-dose caffeine.
Second, normal volunteers report
qualitative differences in caffeine's sub-
jective effects, depending upon dose, as
follows: Low to moderate doses (20-200
mg) produce predominately positive
effects, including increased ratings ofalert-
ness, concentration, desire to talk, energy/
activity, motivation to work, self-confi-
dence, and sense ofwell-being. These doses
also decreased ratings of "muzziness"
(not clearheaded) and sleepiness. High
doses (200-500 mg) produce predomi-
nately dysphoric effects, including ratings
ofincreased anxiety, bad effects, jitteriness,
nervousness, and shakiness (10,11,13,18).
Thus, depending on dose taken in, caffeine
can produce both positive and aversive
effects in the general population.
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Figure 1. Caffeine versus placebo discrimination accuracy as a function of dose in each of seven caffeine-
abstinent, normal subjects. y-axes: percentage correct; x-axes: caffeine dose (milligrams), log scale. Data are
based on the last 20 sessions at each dose. Points overlapping the shaded areas indicate significant discrimination
performance (p< 0.05; binomial test). All doses were administered in descending order, after significant discrimi-
nation at the higher dose. Failure to learn the discrimination at a given dose after 50 sessions terminated a
subject's participation in the study. Figure modified from Griffiths et al. (12).
While the type of subjective effects
produced by caffeine depends upon dose,
the intensity ofcaffeine's subjective effects
may be determined by an individual's sen-
sitivity to low-dose caffeine. That is, there
is a strong negative correlation between an
individual's lowest detectable caffeine dose
(threshold ofdetection) and the magnitude
ofsubjective response to 178 mg caffeine
(r=-0.91) (Figure 2) (12). Thus the lower
the dose ofcaffeine that an individual can
detect, the greater the magnitude of that
individual's response. This relationship
may be particularly important to caffeine-
sensitive MCS patients. That is, individuals
who are able to detect extraordinarily low
caffeine doses may be more likely to report
that dietary doses ofcaffeine produce aver-
sive effects. These results are consistent
with the idea that even low doses of caf-
feine may be strongly aversive to some
caffeine-sensitive individuals.
Finally, although a large proportion of
the population chooses to consume caf-
feine (e.g., > 80% of adults in North
America regularly consume behaviorally
active doses) (15-17), some individuals for
various reasons do not. Individuals who do
not use caffeine may represent a subpopu-
lation for whom dietary doses of caffeine
are aversive, either as a result of an innate
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Figure 2. Graphic illustration of the correlation
between lowest caffeine dose discriminated and mean
magnitude of caffeine effect in seven subjects. y-axis:
mean difference in magnitude of drug effect (178 mg
caffeine minus placebo) on a four-point scale (0 = not
at all; 3 = very much); x-axis: lowest caffeine dose dis-
criminated (milligrams) log scale. Each data point rep-
resents data from a single subject. Caffeine and
placebo were administered five times each, thus each
point represents the mean of five separate scores for
each subject. Previously unpublished figure; data taken
from Mumford et al. (10).
or acquired sensitivity to the drug. In one
study designed to examine reasons for caf-
feine use or nonuse, Goldstein et al. (11)
administered 0, 150, and 300 mg caffeine
to self-reported caffeine users (n = 38) or
nonusers (n = 18). Users reported positive
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subjective effects after caffeine administra-
tion (e.g., increased alertness, decreased
irritability) whereas nonusers reported neg-
ative subjective effects after caffeine admin-
istration (e.g., jitteriness, nervousness).
Evans and Griffiths (18) reported compati-
ble results in a laboratory-based study of32
moderate caffeine users who abstained from
dietary caffeine. In that double-blind study
subjects were challenged on one day with
caffeine (total dose = 600 mg) and on
another day with placebo in color-coded
capsules. Subjects were identified as caffeine
choosers (n = 12) or nonchoosers (n = 20)
based on their choice of placebo- or
caffeine-containing color-coded capsules on
a subsequent choice day. Figure 3 shows
that, after receiving caffeine, nonchoosers'
subjective ratings oftension/anxiety and jit-
tery/nervous/shaky increased relative to
receipt of placebo doses and relative to
choosers' ratings after caffeine administra-
tion. Thus caffeine nonchoosers reported
significantly greater negative effects follow-
ing caffeine challenge than did caffeine
choosers. Both ofthese studies demonstrate
that, in the normal population, a given dose
ofcaffeine can produce aversive effects in
some individuals but not in others.
Caffeine and MCS Patients
MCS patients may represent a population
with an acquired sensitivity to caffeine as
well as other inhaled or ingested chemical
stimuli. As such, when MCS patients are
compared to normal volunteers the MCS
patients could be expected to have a lower
threshold of caffeine detectability and a
greater likelihood of reporting negative
subjective effects to low-dose caffeine.
Certainly these predictions are supported
by self-reports (1). If this hypothesized
sensitivity to caffeine could be demon-
strated using rigorous, double-blind, well
controlled methodology, the syndrome of
MCS would receive some of the empirical
support that some professional medical
organizations suggest it currently lacks.
There are many advantages to using caf-
feine discrimination as a model preparation
to study MCS: caffeine is safe, it can be
conveniently administered in a double-
blind manner, and its pharmacology-at
least in normal humans-is well under-
stood. In contrast, other potential prepara-
tions that might be used to study MCS,
such as airborne challenges with various
chemicals, are less convenient, are often dif-
ficult to deliver in a double-blind manner
due to strong olfactory/gustatory stimuli,
and have less well-known and potentially
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Figure 3. Subjective ratings after receiving placebo (light bars) and caffeine (dark bars) in caffeine choosers
(n=12) and caffeine nonchoosers (n=20). Caffeine doses were 600 mg (300 mg twice daily) for all subjects except
two choosers, who received 400 mg (200 mg twice daily). Subjects were identified as choosers or nonchoosers
based on their choice of placebo- or caffeine-containing color-coded capsules on a subsequent choice day.
Measures are the tension-anxiety scale of the Profile of Moods States and an item (jittery/nervous/shaky) from a
caffeine-sensitive adjective rating scale; each item was ranked on a four-point scale on which 1 = definitely does
not apply; 4 = very strongly applies. Bars show mean data; brackets show +1 SEM. Letters a and b indicate the
results of statistical comparisons among the four conditions; within a panel, any two bars designated with the
same letter are not significantly different from each other at p< 0.05 (Tukey's post-hoc tests). Figure modified from
Evans and Griffiths (18).
less safe pharmacological profiles. The
success of human drug discrimination
studies using caffeine as a discriminative
stimulus in normal humans (10,12,18-20)
suggests that this methodology might be
applied successfully to studies involving
MCS patients. Below we discuss issues rele-
vant to studies that use discrimination
methodology to investigate MCS in the
human behavioral pharmacology laboratory.
Studying Caffeine Sensitivity
in MCS Patients
A study of caffeine sensitivity in MCS
patients could be designed to determine if
self-identified caffeine-sensitive MCS
patients are able to discriminate lower
doses ofcaffeine than normal controls, and
to determine ifthese MCS patients report
aversive effects of caffeine under double-
blind dosing conditions. Such a study
would thus address two unresolved issues
in the MCS literature: the reported sensi-
tivity to usually well-tolerated doses of
chemical stimuli and the lack ofwell-con-
trolled studies demonstrating that low-dose
chemical stimuli elicit the constellation of
symptoms reported by MCS patients.
Studies designed to address these issues
must include carefully crafted instructions
for subjects, may include control groups to
increase the rigor of the study, and may
also include procedures that allow tolerable
dose exposure for all subjects. Each ofthese
ideas is briefly discussed below.
Informed consent is an essential part of
any study involving human subjects and
would be particularly important when
administering caffeine challenges to MCS
patients, since active drug administration
could result in an aversive response. All
subjects must be informed prior to their
participation that they will receive both
placebo and active caffeine-containing cap-
sules throughout the study. However, sub-
jects must also be aware that they may not
be informed of the contents of any given
capsule. Subjects should also be informed
that they must pay attention to the effects
of every dose, as they may be asked to
identify each dose based upon its effects.
One of the strengths of the drug dis-
crimination paradigm is that the intensive
within-subject methodology allows statisti-
cal analysis at the level of the individual.
However, in studies ofspecial populations,
this within-subject methodology may be
enhanced by the addition of a between-
groups component to allow for cross-group
comparison or to control for potential pop-
ulation-specific confounding variables. For
example, a study of caffeine sensitivity in
MCS patients would almost certainly
involve a sample of MCS patients who
report that dietary doses of caffeine elicit
their MCS symptoms. However, such a
group may be caffeine avoidant (21). Thus
non-MCS patients who do not regularly
use caffeine might be included to deter-
mine ifcaffeine avoidance influenced the
observed results. Similarly, a group of
MCS patients who report that they are not
sensitive to caffeine might be considered,
to control for the impact ofMCS diagnosis
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itself. These between-groups comparisons
can help to determine if MCS patients are
differentially sensitive to caffeine.
A study of MCS patients may also
include a comparison group of normal,
moderate caffeine users who abstain from
caffeine throughout the study. One ofthe
primary advantages ofusing a well-accepted
and frequently used methodology is the
ability to compare new results to previous
work. For this reason, normal, moderate
caffeine users might be included in a study
of MCS patients to demonstrate that the
study methodology yielded results similar
to those already in the literature (12,13).
Determination ofa safe and tolerable
training dose is a major issue in any caffeine
discrimination study involving caffeine-sen-
sitive MCS patients. High training doses
may lead to quick acquisition of the dis-
crimination, but may elicit symptoms that
would be intolerable to MCS patients. In
contrast, low training doses may be tolera-
ble but may make the caffeine-placebo dis-
crimination difficult to acquire. Thus
individualizing the training dose after a
brief, ascending dose, threshold-of-detec-
tion phase may be valuable. All subjects
participating in the study could participate
in the threshold-of-detection phase, which
would involve daily administration of a
single capsule containing either placebo or
active caffeine. The primary goal of this
phase would be to determine safe and toler-
able doses ofcaffeine that might be used in
a later discrimination phase. Ideally, the
ratio ofplacebo to active drug trials in the
threshold-of-detection phase would be
high, to determine a base rate ofplacebo
responding (i.e., false positives) and to
allow for adequate washout time between
active doses. Also, initial doses ofactive caf-
feine might be lower than doses to which
the general population is sensitive, because
one hypothesis ofthe study is that caffeine-
sensitive MCS patients are more sensitive to
caffeine than the general population. An
example of a threshold-of-detection phase
might involve a 4:1 placebo:active dose
ratio, with the amount ofactive dose rang-
ing from 1.0 to 100.0 mg caffeine. Sessions
would involve administration of a single
capsule, followed by subjective ratings of
drug effects and attempts to identify the
presence or absence ofactive caffeine. Once
an individual has correctly detected an
active dose, that correct detection should be
replicated several times to reduce the possi-
bility ofa chance identification. This phase
would yield only preliminary results, useful
for planning safe and tolerable discrimina-
tion training. Assuming that subjects are
willing to repeatedly self-administer their
individually determined threshold dose,
discrimination training could begin.
Discrimination training, during which
subjects learn to discriminate placebo from
the effects ofactive drug, is the heart ofany
drug discrimination study. During train-
ing, subjects are presented with placebo
and tolerable active drug doses (determined
from the threshold ofdetection phase) that
have been previously identified by a letter
code. Subjects earn money for correctly
identifying (by code letter) which com-
pound they received on each day (13). The
discrimination is said to be learned when
subjects correctly identify some criterion
percentage (e.g., > 80% of more than 10
presentations) ofpresented capsules. Ifthe
discrimination is not learned, a higher
active dose is used and the process is
repeated. Once a discrimination at a given
dose has been learned, subjects repeat the
procedure using a lower active dose. In this
manner, the lowest discriminable dose for
each individual can be determined
(10,12,13), and any potential differences
in discriminable doses between groups
(e.g., MCS patients vs normal controls)
can be examined. Thus, drug discrimina-
tion methodology can be used to deter-
mine ifMCS patients are more sensitive to
caffeine than various control groups. Also,
the addition of concurrent subjective mea-
sures would permit the determination of
the types of responses elicited by caffeine
challenge in MCS patients and would
allow comparison to the caffeine-elicited
responses ofvarious control groups.
The wide variety of chemical stimuli
that may elicit MCS symptoms increases
the potential for extraneous variability in a
laboratory study ofMCS patients. Stimuli
encountered during normal daily activity
or in the laboratory may elicit MCS symp-
toms that could be mistakenly attributed to
the study drug. To avoid this potential
bias, drug discrimination studies ofMCS
patients may involve sessions that all sub-
jects run in their own homes. Subjects
would be able to pick up a supply ofstudy
forms and capsules, and conduct sessions
in an environment that is relatively free of
symptom-eliciting environmental stimuli.
Scheduling ofsessions would be subject-
determined, so that no sessions would
take place when an MCS patient was
symptomatic; environmentally induced
MCS symptoms may mask the symptoms
produced by the study drug (21).
Conclusions
MCS patients and their physicians will
both benefit from rigorous, well-controlled
research designed to empirically address the
validity of the MCS diagnosis. Caffeine
discrimination studies are one example ofa
research program that could better charac-
terize an ill-defined disorder. Regardless of
the outcome, well-designed empirical
studies ofMCS can improve diagnostic and
treatment techniques. Studies that fail to
demonstrate the reproducibility ofthe dis-
order under rigorous laboratory conditions
will suggest that symptoms might best be
attributed to a cause other than toxicity of
chemical stimuli. Studies that demonstrate
the reproducibility ofthe disorder under
rigorous laboratory conditions will support
the MCS diagnosis, improve acceptance of
the disorder within the medical community,
and lead to effective treatments through
continued research.
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